A Study of ES104 in Patients With Metastatic Colorectal Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

ES104

ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

DRUG

ES104

ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

DRUG

ES104

ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Elpiscience (Suzhou) Biopharma, Ltd.

INDUSTRY